Cytokinetics plans $650M public offering of common stock to fund cardiovascular drug development.

Cytokinetics, a biopharmaceutical company specializing in cardiovascular treatments, announced a proposed public offering of approximately $650 million in common stock, subject to market conditions. The offering aims to support the development of its cardiac muscle drugs, including the approved MYQORZO® and investigational treatments like omecamtiv mecarbil and ulacamten. The company has engaged major banks as underwriters and may grant them an option to purchase additional shares. Completion and terms depend on market conditions and regulatory approvals.